Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Astrazeneca Plc (AZN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Ironwood Begins New Phase III Study to Expand Linzess Label

Ironwood (IRWD) commences a phase IIIb study in order to add a couple of new symptoms like bloating and discomfort associated with IBS-C to Linzess' label.

IRWD : 20.02 (-0.20%)
AZN : 37.17 (+0.38%)
AGN : 171.79 (-0.92%)
TARO : 112.94 (-0.72%)
Novartis Looks to Exit Antibacterial, Antiviral Program

Per media sources, Novartis is looking to exit its antibacterial and antiviral research program, and cut its headcount.

AZN : 37.17 (+0.38%)
AGN : 171.79 (-0.92%)
NVS : 82.27 (+1.82%)
PFE : 37.33 (-0.08%)
Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit

Pfizer (PFE) is re-organizing its business into three new units, effective 2019. A St Louis jury orders J&J (JNJ) to pay $4.69 billion in a lawsuit related to its talc-based products.

CTIC : 2.35 (+3.52%)
AZN : 37.17 (+0.38%)
JNJ : 125.85 (-0.07%)
MRK : 62.52 (+0.02%)
ABBV : 88.91 (-1.16%)
PFE : 37.33 (-0.08%)
BMY : 56.71 (+0.30%)
Biogen's Alzheimer Disease Candidate Succeeds in Phase II

Biogen's (BIIB) Alzheimer's disease (AD) candidate demonstrates statistically significant slowdown in disease progression and reduction of amyloid beta accumulation in the brain in a phase II study.

AZN : 37.17 (+0.38%)
JNJ : 125.85 (-0.07%)
LLY : 88.47 (-1.07%)
BIIB : 358.71 (+0.17%)
Clovis Gets EU Acceptance for Rubraca Label Expansion Filing

Clovis Oncology's (CLVS) regulatory application seeking label expansion of Rubraca as maintenance treatment was accepted for review in Europe.

AZN : 37.17 (+0.38%)
CLVS : 47.87 (+1.76%)
TSRO : 39.24 (-2.46%)
PFE : 37.33 (-0.08%)
Pharma Stock Roundup: NVS to Divest Eye Care Unit, CHMP Gives Nod to Several Drugs

Novartis (NVS) intends to spin off its Alcon eye care division. The CHMP gives positive opinion recommending marketing approval to several drugs.

AZN : 37.17 (+0.38%)
JNJ : 125.85 (-0.07%)
MRK : 62.52 (+0.02%)
ADMP : 3.80 (+4.11%)
NVS : 82.27 (+1.82%)
GSK : 41.87 (+2.90%)
BMY : 56.71 (+0.30%)
AstraZeneca's Two New Cancer Drugs Get Approval in Japan

AstraZeneca gets approval in Japan for two new cancer drugs. These include Lynparza for a breast cancer indication and Imfinzi for an early-stage lung cancer indication.

AZN : 37.17 (+0.38%)
MRK : 62.52 (+0.02%)
ABBV : 88.91 (-1.16%)
PFE : 37.33 (-0.08%)
Dow 30 Stock Roundup: Nike, Walgreens Earnings Impress

The Dow endured a turbulent week, marked by lingering trade tensions.

FOXA : 46.00 (-1.39%)
AZN : 37.17 (+0.38%)
JPM : 111.28 (+1.26%)
INTC : 51.91 (-0.13%)
WBA : 64.98 (+0.08%)
NKE : 76.96 (+0.01%)
GS : 231.69 (+0.90%)
PFE : 37.33 (-0.08%)
UNH : 252.70 (-0.09%)
DIS : 111.48 (-0.58%)
BA : 354.90 (-0.12%)
Blog Exposure - AstraZeneca's LYNPARZA(R) Reports Encouraging Results from Phase-III 1st-Line SOLO-1 Trial for Advanced Ovarian Cancer

LONDON, UK / ACCESSWIRE / June 29, 2018 / If you want access to our free research report on AstraZeneca PLC (NYSE: ), all you need to do is sign up now by clicking the following link as the Company's...

AZN : 37.17 (+0.38%)
AstraZeneca/Merck's Lynparza Betters Survival in Phase III

AstraZeneca (AZN) and Merck's (MRK) Lynparza significantly delays disease progression in a late-stage study evaluating it for the first-line treatment of advanced ovarian cancer.

AZN : 37.17 (+0.38%)
MRK : 62.52 (+0.02%)
CLVS : 47.87 (+1.76%)
TSRO : 39.24 (-2.46%)
LYNPARZA(R) (olaparib) Significantly Delays Disease Progression in Phase III 1st-Line SOLO-1 Trial for Ovarian Cancer

--AstraZeneca and Merck's LYNPARZA is the only PARP inhibitor to demonstrate significant activity in the 1st-line maintenance setting

AZN : 37.17 (+0.38%)
MRK : 62.52 (+0.02%)
Pfizer's Breast Cancer Drug Misses Overall Survival in Study

Pfizer (PFE) announces that in the phase III PALOMA-3 study, the combination of Ibrance and Faslodex failed to improve overall survival in women with breast cancer compared with Faslodex and placebo.

AZN : 37.17 (+0.38%)
NVS : 82.27 (+1.82%)
ANIP : 70.49 (-0.10%)
PFE : 37.33 (-0.08%)
Merrimack Crashes as Phase II Pancreatic Cancer Study Fails

Merrimack (MACK) plunges, following the announcement of failure of the CARRIE phase II study on pipeline candidate, MM-141, for the treatment of metastatic pancreatic cancer.

AGLE : 9.20 (-1.18%)
AZN : 37.17 (+0.38%)
ANIP : 70.49 (-0.10%)
MACK : 5.22 (-1.51%)
Merck (MRK) Presents New Data from Januvia Diabetes Studies

Merck (MRK) produces new data from two studies on type II diabetes medicine Januvia (sitagliptin), which supports the drug's clinical profile.

AZN : 37.17 (+0.38%)
MRK : 62.52 (+0.02%)
LLY : 88.47 (-1.07%)
HLUYY : 70.1600 (+0.01%)
FARXIGA in Combination with ONGLYZA Demonstrates Similar Glycemic Control with Additional Benefits Vs. Insulin Glargine in Patients with Type 2 Diabetes

AstraZeneca (NYSE: AZN) presented key data on the use of FARXIGA(R) (dapagliflozin) in diverse patient populations with type 2 and type 1 diabetes (T2D, T1D) at the American Diabetes Association...

AZN : 37.17 (+0.38%)
Ironwood Initiates Phase III Studies on Reflux Candidate

Ironwood (IRWD) initiates two phase III studies on its gastrointestinal candidate, IW-3718, to evaluate it in persistent gastroesophageal reflux disease.

AGLE : 9.20 (-1.18%)
IRWD : 20.02 (-0.20%)
AZN : 37.17 (+0.38%)
PG : 78.68 (-0.06%)
Merck (MRK) Stock Up So Far This Year on Keytruda Strength

Merck's shares are up 8.4% this year driven by strong performance and positive regulatory updates related to its PD-1 inhibitor, Keytruda.

AZN : 37.17 (+0.38%)
MRK : 62.52 (+0.02%)
LLY : 88.47 (-1.07%)
AMGN : 190.49 (-0.66%)
Novo Nordisk's (NVO) Oral Ozempic Positive in Diabetes Study

Novo Nordisk (NVO) announces positive headline results of two phase III studies PIONEER oral formulation of Ozempic (semaglutide) as a treatment for adults with type II diabetes.

AGLE : 9.20 (-1.18%)
AZN : 37.17 (+0.38%)
NVO : 50.44 (+1.26%)
LLY : 88.47 (-1.07%)
Initiating Free Research Reports on Bristol-Myers Squibb and Three Other Drug Makers Equities

Stock Research Monitor: ABBV, AZN, and LLY

AZN : 37.17 (+0.38%)
LLY : 88.47 (-1.07%)
ABBV : 88.91 (-1.16%)
BMY : 56.71 (+0.30%)
Valeant Down as FDA Refuses to Approve Duobrii For Psoriasis

Valeant (VRX) suffers a setback as the FDA issues a CRL for its plaque psoriasis lotion, Duobrii.

AGLE : 9.20 (-1.18%)
AZN : 37.17 (+0.38%)
ILMN : 311.15 (+0.66%)
VRX : 23.40 (-3.43%)

Van Meerten Stock Picks

5 Terrific Mid Caps
In this roller coaster market I wanted to find Mid Cap stocks that had consistent price appreciation over the last 6 month period.
EHC -0.38 , FTNT +0.53 , CAKE -0.45 , PLT -0.28 , AEO -0.65
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Agricharts Market Commentary

Today's Commentary

Corn futures closed the week with most contracts 3 to 4 cents higher on Friday. Nearby September was up 4.1% since last Friday, with higher closes every day this week. Solid exports and drier weather fueled some bottom picking and short covering acti...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar